Expression of Her-2/neu in Colon Carcinoma and Its Correlation with the Histological Grades and the Lymph Nodes Status
Published: December 1, 2011 | DOI: https://doi.org/10.7860/JCDR/2011/.1729
Manmeet Kaur Gill, Kalpana Jain, Mridu Manjari, Tanveer Kaur
1. MD, Pathology, Assistant Professor, Department of Pathology, AIMSR, Bathinda, India.
2. DNB, Pathology, Department of Pathology, AIMSR,Bathinda, India.
3. MD, Pathology Department of Pathology, SGRD, Amritsar, India.
4. BDS, Department of Periodontics, CDSH,Rau-Indore, India.
Correspondence
Manmeet Kaur Gill,
H.N. 22265/A, Shant Nagar, Bathinda,
Punjab, India.
Phone: 9876610985
E-mail: drmanmeet27@yahoo.co.in
Background and Objective: This study was done to check the expression of Her-2/neu in colon carcinoma and its correlation with the histological grades and lymph node metastasis. Colon cancer is the third prevalent cancer in men and women and it is a leading cause of morbidity and mortality in both. Her-2/neu is a useful antigenic marker in immunological studies of colon carcinoma and it can be used for predicting the prognosis and the treatment.
Materials and Methods: The present study was conducted on 40 cases of histopathologically proven colon carcinoma cases to check for Her-2/neu expression by using the novocastra kit.Both cytoplasmic as well as membranous staining were considered as positive for colon cancer.
Results: Her-2/neu was positive in 65% of the cases. It was seen in 68.75% cases of well differentiated, 53.84% cases of moderately differentiated and 100% cases of poorly differentiated conventional adenocarcinomas. Mucinous carcinomas showed more positivity (71.4%)for Her-2/neu as compared to conventional adenocarcinomas (64.5%). The positivity was more in the grade III tumours as compared to that in the other grades. All the colorectal carcinoma cases with metastatic nodes were positive for Her-2/neu staining.
Conclusion: Thus, it was concluded that colorectal carcinomas, especially those with lymph node metastasis, should be subjected to Her-2/neu expression studies, as the tumours which expressed Her-2/neu could carry a poor prognosis and therefore would require a different therapeutic approach, as these cases could respond to Trastuzumab (Herceptin) therapy.
[
FULL TEXT ] | [ PDF]